Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vertiv Holdings Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.99 (market cap $772.39M), while Vertiv Holdings Co trades at $248.87 (market cap $94.90B). The key difference: Vertiv Holdings Co is far larger — about 122.9× Ginkgo Bioworks Holdings Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Vertiv Holdings Co for 39 Days on average.
| DNA | VRT | |
|---|---|---|
Market Cap | $772.39M | $94.90B |
Volume | 6,453,273 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $15.83 | $376.23 |
52-Week Low | $5.48 | $149.83 |
Typical Hold Time | 7 Days | 39 Days |
Enterprise Value | $874.34M | $95.12B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
